机构名称：
¥ 2.0
• Our discussions during this presentation include forward-looking statements about our anticipated operating and financial performance, business plans and prospects, expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, revenue contribution, growth, performance, timing of exclusivity and potential benefits, and our efforts to respond to COVID-19, including our development of a vaccine to help prevent COVID-19，每种都有很大的风险和不确定性，这些风险可能导致实际结果与此类陈述所表示或暗示的结果有实质性差异。除其他外，关于收入和每股收益增长的陈述；我们的产品管道，在线产品，候选产品和其他指示的开发或商业潜力，包括预期的临床试验方案，临床试验的启动和进度的时机以及试验的数据读数；提交法规批准的申请和收到的时间；预期的突破，最佳或一流的地位，我们药物的大片状态；预期改善对我们的临床运营绩效的影响是前瞻性的，并且是估计会发生变化，临床试验和监管成功。这些陈述受风险，不确定性和其他因素的影响，这些因素可能导致实际结果与过去的结果，未来计划和预计未来结果有实质性差异。Additional information regarding these and other factors can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in our subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in our subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov和www.pfizer.com。潜在的风险和不确定性还包括Covid-19对我们的销售和运营的影响，包括对员工，制造业，供应链，市场营销，研发以及临床试验的影响。
辉瑞肿瘤学分析师和投资者会议
主要关键词
相关文件推荐
